Timothy G. Youngquist 2020 Irrevocable Trust Has $14.99 Million Position in Relay Therapeutics, Inc. $RLAY

Timothy G. Youngquist 2020 Irrevocable Trust increased its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) by 60.6% in the second quarter, Holdings Channel.com reports. The institutional investor owned 801,464 shares of the company’s stock after buying an additional 302,406 shares during the period. Relay Therapeutics makes up 2.9% of Timothy G. Youngquist 2020 Irrevocable Trust’s holdings, making the stock its 5th biggest holding. Timothy G. Youngquist 2020 Irrevocable Trust’s holdings in Relay Therapeutics were worth $14,995,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Meeder Asset Management Inc. bought a new stake in Relay Therapeutics in the 2nd quarter valued at about $62,000. BlackRock Inc. purchased a new stake in Relay Therapeutics in the 2nd quarter valued at $286,042,000. Pallas Capital Advisors LLC purchased a new stake in shares of Relay Therapeutics in the second quarter valued at about $413,000. Deutsche Bank AG purchased a new stake in Relay Therapeutics in the 2nd quarter valued at about $3,069,000. Finally, Alphabet Inc. purchased a new stake in shares of Relay Therapeutics during the second quarter valued at approximately $26,382,000. 96.98% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Relay Therapeutics

In other Relay Therapeutics news, insider Peter Rahmer sold 50,000 shares of Relay Therapeutics stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $19.09, for a total transaction of $954,500.00. Following the completion of the transaction, the insider owned 225,857 shares in the company, valued at approximately $4,311,610.13. The trade was a 18.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Thomas Catinazzo sold 187,163 shares of Relay Therapeutics stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $16.97, for a total value of $3,176,156.11. Following the completion of the transaction, the chief financial officer directly owned 177,461 shares of the company’s stock, valued at approximately $3,011,513.17. This represents a 51.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 409,639 shares of company stock valued at $7,233,399. Insiders own 5.04% of the company’s stock.

Relay Therapeutics Trading Down 0.3%

Shares of NASDAQ RLAY opened at $20.61 on Wednesday. Relay Therapeutics, Inc. has a 12 month low of $3.31 and a 12 month high of $20.99. The firm has a market capitalization of $4.52 billion, a PE ratio of -13.13 and a beta of 1.69. The firm has a fifty day simple moving average of $18.51 and a two-hundred day simple moving average of $14.14.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.96 million. On average, sell-side analysts predict that Relay Therapeutics, Inc. will post -1.58 earnings per share for the current year.

Wall Street Analyst Weigh In

RLAY has been the topic of several research reports. Guggenheim reaffirmed a “buy” rating on shares of Relay Therapeutics in a research report on Friday, August 7th. The Goldman Sachs Group boosted their price objective on Relay Therapeutics from $22.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Canaccord Genuity Group assumed coverage on shares of Relay Therapeutics in a report on Thursday, July 16th. They set a “buy” rating and a $29.00 target price on the stock. Barclays raised their price target on Relay Therapeutics from $27.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, JonesTrading upgraded shares of Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $25.83.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.